FDA approves RYTELO™ (imetelstat) for treating lower-risk MDS with transfusion-dependent anemia.

Geron Corporation announces FDA approval of RYTELO™ (imetelstat), a first-in-class telomerase inhibitor, for treating adult patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia who haven't responded to or lost response to erythropoiesis-stimulating agents (ESA). This approval aims to provide eligible patients with potential freedom from red blood cell transfusions for over 24 weeks.